← Leaderboards
Alain H Rook
University Of Pennsylvania
$9,745,732
Attributed
$11,061,181
Total exposure
13
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $576.8K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$10,665,933 · 12
FDA$395,248 · 1
By mechanism
R01$8,721,965 · 5
M01$1,090,864 · 4
K24$626,005 · 1
R21$536,581 · 2
P50$85,766 · 1
Top collaborators
- Rachael Ann Clark4 shared
- Joel M Gelfand2 shared
- Maria Wysocka2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Maria Wysocka$188,791
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectInterleukin 12Human Therapy EvaluationMycosis Fungoides LymphomaClinical ResearchRecombinant ProteinsApoptosisNatural Killer CellsSkinCytokineFlow CytometryReceptor ExpressionNeoplasm /Cancer ImmunotherapyMalignant NeoplasmsCellsResponseT-LymphocyteDrug Screening /EvaluationImmunologicsImmuneInterferon GammaDendritic CellsBloodInterferon Alpha
Grant awards (50)
Reversing immune evasion and enhancing immune detection with topical resiquimod$438,084
R01 · FY2021 · AR
Reversing immune evasion and enhancing immune detection with topical resiquimod$452,618
R01 · FY2020 · AR
Reversing immune evasion and enhancing immune detection with topical resiquimod$453,584
R01 · FY2019 · AR
Reversing immune evasion and enhancing immune detection with topical resiquimod$513,783
R01 · FY2018 · AR
CD164 as a novel biomarker for malignant CD4 T cells in cutaneous T cell lymphoma$168,781
R21 · FY2014 · CA
CD164 as a novel biomarker for malignant CD4 T cells in cutaneous T cell lymphoma$208,800
R21 · FY2013 · CA
Phase 1 Study of Resiquimod Gel Therapy for Cutaneous T-Cell Lymphoma$196,942
R01 · FY2013 · FD · contact PI
Phase 1 Study of Resiquimod Gel Therapy for Cutaneous T-Cell Lymphoma$198,306
R01 · FY2012 · FD · contact PI
Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma$259,920
R01 · FY2011 · CA · contact PI
Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma$263,664
R01 · FY2010 · CA · contact PI
Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma$269,612
R01 · FY2009 · CA · contact PI
Toll Receptor Ligand Therapy of Cutaneous T-Cell Lymphoma$283,500
R01 · FY2008 · CA · contact PI
Immunotherapy of Cutaneous T-Cell Lymphoma with Interleukin-12$3
P50 · FY2008 · CA · contact PI
Dendritic cell defects in cutaneous T-cell lymphoma$332,837
R01 · FY2007 · CA · contact PI
Immunotherapy of Cutaneous T-Cell Lymphoma with Interleukin-12$6
P50 · FY2007 · CA · contact PI
Dendritic cell defects in cutaneous T-cell lymphoma$334,574
R01 · FY2006 · CA · contact PI
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma$242,274
R01 · FY2006 · CA · contact PI
Immunotherapy of Cutaneous T-Cell Lymphoma w$1
P50 · FY2006 · CA · contact PI
Dendritic cell defects in cutaneous T-cell lymphoma$334,469
R01 · FY2005 · CA
Immunotherapy of Cutaneous T-Cell Lymphoma w$42,878
P50 · FY2005 · CA
RECOMBINANT HUMAN IL-12 IN MYCOSIS FUNGOIDES$16,021
M01 · FY2005 · RR
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma$829,822
R01 · FY2004 · CA
Dendritic cell defects in cutaneous T-cell lymphoma$326,552
R01 · FY2004 · CA
CYTOKINE THERAPY OF CUTANEOUS T CELL LYMPHOMA$125,201
K24 · FY2004 · CA
Immunotherapy of Cutaneous T-Cell Lymphoma w$42,878
P50 · FY2004 · CA
Recombinant Human IL-12 in Mycosis Fungoides$1,065
M01 · FY2004 · RR
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma$849,362
R01 · FY2003 · CA
Dendritic cell defects in cutaneous T-cell lymphoma$333,491
R01 · FY2003 · CA
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma$137,781
R01 · FY2003 · CA
CYTOKINE THERAPY OF CUTANEOUS T CELL LYMPHOMA$125,201
K24 · FY2003 · CA
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma$803,305
R01 · FY2002 · CA
CYTOKINE THERAPY OF CUTANEOUS T CELL LYMPHOMA$125,201
K24 · FY2002 · CA
RECOMBINANT INTERLEUKIN 12 IN PATIENTS W/ STAGE IA, IB OF IIA MYCOSIS$124,146
M01 · FY2002 · RR
Effects of interleukin 12 in cutaneous t cell lymphoma$0
P50 · FY2002 · CA
Recombinant Interleukin-12 for Cutaneous T-Cell Lymphoma$867,485
R01 · FY2001 · CA
CYTOKINE THERAPY OF CUTANEOUS T CELL LYMPHOMA$125,201
K24 · FY2001 · CA
RECOMBINANT INTERLEUKIN 12 IN PATIENTS W/ STAGE IA, IB OF IIA MYCOSIS$124,146
M01 · FY2001 · RR
Effects of interleukin 12 in cutaneous t cell lymphoma$0
P50 · FY2001 · CA
RECOMBINANT INTERLEUKIN 12 IN PATIENTS W/ STAGE IA, IB OF IIA MYCOSIS$0
M01 · FY2001 · RR
PHOTOPHORESIS WITH LIQUID 8-METHOXSALEN IN SYSTEMIC SCLEROSIS$187,536
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN CUTANEOUS T CELL LYMPHOMA$187,536
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN CUTANEOUS T CELL LYMPHOMA$187,536
M01 · FY2000 · RR
PHOTOPHORESIS WITH LIQUID 8-METHOXSALEN IN SYSTEMIC SCLEROSIS$187,536
M01 · FY2000 · RR
INTERLEUKIN 12 THERAPY OF CUTANEOUS T CELL LYMPHOMA$159,000
R21 · FY2000 · CA
CYTOKINE THERAPY OF CUTANEOUS T CELL LYMPHOMA$125,201
K24 · FY2000 · CA
PHOTOPHORESIS WITH LIQUID 8-METHOXSALEN IN SYSTEMIC SCLEROSIS$25,114
M01 · FY2000 · RR
RECOMBINANT INTERLEUKIN 12 IN PATIENTS W/ STAGE IA, IB OF IIA MYCOSIS$25,114
M01 · FY2000 · RR
RECOMBINANT HUMAN INTERLEUKIN 12 IN CUTANEOUS T CELL LYMPHOMA$25,114
M01 · FY2000 · RR
RECOMBINANT INTERLEUKIN 12 IN PATIENTS W/ STAGE IA, IB OF IIA MYCOSIS$0
M01 · FY2000 · RR
RECOMBINANT INTERLEUKIN 12 IN PATIENTS W/ STAGE IA, IB OF IIA MYCOSIS$0
M01 · FY2000 · RR